Search results
Earnings call: Inhibikase Therapeutics reports on drug trials progress
Investing.com· 24 hours agoInhibikase Therapeutics, a biopharmaceutical company focused on developing treatments for...
Inhibikase halts plans for public offering of securities By Investing.com
Investing.com· 4 days agoInhibikase Therapeutics, Inc. (NASDAQ:IKT), a biopharmaceutical company focused on developing...
FDA grants breakthrough therapy status for Nuvalent’s NVL-655
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for...
Hyperpigmentation on your neck? It could be your fragrance
Cosmo via Yahoo News· 1 day agoHyperpigmentation on your neck? Your fragrance might be the cause. Here the experts explain how...
The Best Appetite Suppressants and Diet Pills To Control Hunger and Boost Metabolism in 2024
Men's Journal· 3 days agoCurb cravings and sustain your energy with safe and effective appetite suppressants. When paired...
FDA rejects liver cancer drug combo, shares of Korean biotech tank
Endpoints News· 2 days agoKorean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the...
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Pharmaceutical Technology via Yahoo Finance· 6 days agoAugtyro, an orally administered tyrosine kinase inhibitor (TKI) designed to inhibit specific kinases...
InnoCare Pharma concludes subject enrolment Phase II psoriasis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThis marks a significant milestone in the development of the drug, which is a tyrosine kinase 2...
Fruit fly testes enzyme could stymie harmful pests
Futurity· 5 days agoAn enzyme from fruit fly testes could control bugs that carry disease and harm crops by stunting their ability to procreate, researchers report. “We have...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 4 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...